NCT05114265View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
Acute Pain
Interventions
DRUG

KUR-101

Single oral dose of KUR-101

DRUG

OxyNorm

Single oral dose of OxyNorm

DRUG

Placebo

Single oral dose of placebo

Trial Locations (1)

8011

KUR-101-101 Clinical Research Site, Christchurch

All Listed Sponsors
lead

Kures, Inc.

INDUSTRY